ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0871

Mitochondrial Transfer Functionally Restores the Human Osteoarthritis (OA) Chondrocyte, Is Protective Against Oxidative Stress and Improves OA in a Clinical Model of Disease

Fernando Figueroa1, Angela Court2, Patricia Luz Crawford2, Ana Maria Vega Letter2, Francesca Velarde2, Cynthia Garcia2 and Maroun Khoury2, 1IMPACT, Santiago de Chile, Chile, 2IMPACT, Santiago, Chile

Meeting: ACR Convergence 2023

Keywords: Cartilage Repair, chondrocyte, Mesenchymal stem cells, Mitochondrial Dysfunction, Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: (0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthrosis (OA) is a leading cause of pain, disability and early mortality, with no disease modifying treatments. Mitochondrial dysfunction is a known driver of disease. Mesenchymal stromal cells (MSCs) -widely tested in OA- transfer their mitochondria (MT) to damaged tissues in response to stress. Aim: To characterize the functional impact of MT transfer (MitoT) from umbilical cord-derived MSC (MSCs) to the human OA chondrocyte (OA-Ch) and clinical effect of MSC-derived MT in a murine model of OA.

Methods: Primary chondrocytes from OA patient surgery were tested for MitoT using in vitro co-culture with MSCs. MitoT was evidenced by flow cytometry and confocal microscopy of MitoTracker stained and YPF-tagged MT protein. To single out effects of MitoT on target cells, we employed direct transfer of MSC-derived MT to OA-Chs (Mitoception). The response of target cells was gauged by ATP production, oxygen consumption (OCR), extracellular acidification (ECAR) rates, levels of reactive oxygen species (ROS) superoxide dismutase (SOD), MT network fussion/fission and OA-Ch viability by TUNEL assays. Intra-articular injection of MSC-derived MT was tested in a collagenase induced murine model of OA.

Results: Dose-dependent cell-to-cell MitoT from MSCs to cultured OA-Chs was detected starting at 4 hours of co-culture, with increasing (3.2x) MT-fluorescence levels at higher MSC:Ch ratios. PCR analysis confirmed the presence of exogenous MSC-MT within MitoT+ OA-Chs up to 9 days post Mitoception. Metabolic analysis showed a 2x increase (p< 0.001) in ATP and a higher OXPHOS/Glycolysis ratio (p=0.0213) in target OA-Chs revealing a switch towards an activated energy state of chondrocytes after MitoT. Increased SOD2 mRNA transcripts (p< 0.05), protein levels (1.8-fold), MT-SOD activity (2.9-fold) and reduced ROS levels (p=0.039) were coincident with enhanced resistance of OA-Chs to apoptosis, indicating this effect of MitoT is related to the control of ROS. In parallel, the change in mRNA transcripts and proteins that control the fusion/fission state of the MT network, showed increased expression of MFN2 (p< 0.01) and decreased p-DRP1 (p< 0.05) that promote a predominantly fused MT network, that contributes to chondrocyte preservation. In the preclinical OA model, intra-articular treatment with MSC-derived MT improved histologic scores (p< 0.001) and MicroCT imaging of the diseased joints (p< 0.01).

Conclusion: MSC-derived MT transferred to the OA-Ch convey significant changes in energy balance, MT dynamics, resistance to oxidative stress and OA-Ch apoptosis. Intra-articular MT treatment improved disease in a murine model of OA. These findings might represent a new strategy in the treatment of this disease.


Disclosures: F. Figueroa: None; A. Court: None; P. Luz Crawford: None; A. Vega Letter: Innovacell, 3; F. Velarde: None; C. Garcia: None; M. Khoury: Cells for Cells SA, 4, 5, 10.

To cite this abstract in AMA style:

Figueroa F, Court A, Luz Crawford P, Vega Letter A, Velarde F, Garcia C, Khoury M. Mitochondrial Transfer Functionally Restores the Human Osteoarthritis (OA) Chondrocyte, Is Protective Against Oxidative Stress and Improves OA in a Clinical Model of Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/mitochondrial-transfer-functionally-restores-the-human-osteoarthritis-oa-chondrocyte-is-protective-against-oxidative-stress-and-improves-oa-in-a-clinical-model-of-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mitochondrial-transfer-functionally-restores-the-human-osteoarthritis-oa-chondrocyte-is-protective-against-oxidative-stress-and-improves-oa-in-a-clinical-model-of-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology